Cargando…

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma

PURPOSE: There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenter, Vera, Albert, Nathalie L., Unterrainer, Marcus, Ahmaddy, Freba, Ilhan, Harun, Jellinek, Annamirl, Knösel, Thomas, Bartenstein, Peter, Spitzweg, Christine, Lehner, Sebastian, Todica, Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835150/
https://www.ncbi.nlm.nih.gov/pubmed/32683470
http://dx.doi.org/10.1007/s00259-020-04952-2
_version_ 1783642452701216768
author Wenter, Vera
Albert, Nathalie L.
Unterrainer, Marcus
Ahmaddy, Freba
Ilhan, Harun
Jellinek, Annamirl
Knösel, Thomas
Bartenstein, Peter
Spitzweg, Christine
Lehner, Sebastian
Todica, Andrei
author_facet Wenter, Vera
Albert, Nathalie L.
Unterrainer, Marcus
Ahmaddy, Freba
Ilhan, Harun
Jellinek, Annamirl
Knösel, Thomas
Bartenstein, Peter
Spitzweg, Christine
Lehner, Sebastian
Todica, Andrei
author_sort Wenter, Vera
collection PubMed
description PURPOSE: There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT). METHODS: We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival. RESULTS: Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0–19.8) vs. 20.1 years (95% CI 19.0–21.1) in FTC patients (p value 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309–0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years). CONCLUSIONS: Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT.
format Online
Article
Text
id pubmed-7835150
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78351502021-01-29 Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma Wenter, Vera Albert, Nathalie L. Unterrainer, Marcus Ahmaddy, Freba Ilhan, Harun Jellinek, Annamirl Knösel, Thomas Bartenstein, Peter Spitzweg, Christine Lehner, Sebastian Todica, Andrei Eur J Nucl Med Mol Imaging Original Article PURPOSE: There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT). METHODS: We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival. RESULTS: Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0–19.8) vs. 20.1 years (95% CI 19.0–21.1) in FTC patients (p value 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309–0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years). CONCLUSIONS: Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT. Springer Berlin Heidelberg 2020-07-18 2021 /pmc/articles/PMC7835150/ /pubmed/32683470 http://dx.doi.org/10.1007/s00259-020-04952-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Wenter, Vera
Albert, Nathalie L.
Unterrainer, Marcus
Ahmaddy, Freba
Ilhan, Harun
Jellinek, Annamirl
Knösel, Thomas
Bartenstein, Peter
Spitzweg, Christine
Lehner, Sebastian
Todica, Andrei
Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title_full Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title_fullStr Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title_full_unstemmed Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title_short Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
title_sort clinical impact of follicular oncocytic (hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835150/
https://www.ncbi.nlm.nih.gov/pubmed/32683470
http://dx.doi.org/10.1007/s00259-020-04952-2
work_keys_str_mv AT wentervera clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT albertnathaliel clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT unterrainermarcus clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT ahmaddyfreba clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT ilhanharun clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT jellinekannamirl clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT knoselthomas clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT bartensteinpeter clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT spitzwegchristine clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT lehnersebastian clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma
AT todicaandrei clinicalimpactoffollicularoncocytichurthlecellcarcinomaincomparisonwithcorrespondingclassicalfollicularthyroidcarcinoma